Dae Gon Ha
Stock Analyst at Stifel
(2.79)
# 1,771
Out of 5,122 analysts
54
Total ratings
38.46%
Success rate
10.66%
Average return
Main Sectors:
Stocks Rated by Dae Gon Ha
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MIRM Mirum Pharmaceuticals | Maintains: Buy | $92 → $98 | $103.96 | -5.73% | 5 | Dec 16, 2025 | |
| ABEO Abeona Therapeutics | Maintains: Buy | $21 → $20 | $5.08 | +293.70% | 2 | May 16, 2025 | |
| EDIT Editas Medicine | Downgrades: Hold | $11 → $3 | $1.95 | +53.85% | 4 | Dec 13, 2024 | |
| SLNO Soleno Therapeutics | Maintains: Buy | $59 → $74 | $42.12 | +75.69% | 2 | Oct 1, 2024 | |
| FULC Fulcrum Therapeutics | Downgrades: Hold | $22 → $3 | $9.90 | -69.70% | 4 | Sep 12, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $80 → $64 | $12.36 | +417.80% | 2 | Sep 11, 2024 | |
| KRYS Krystal Biotech | Maintains: Buy | $204 → $220 | $269.13 | -18.26% | 4 | Sep 11, 2024 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $124 → $127 | $24.69 | +414.38% | 2 | May 31, 2024 | |
| RCKT Rocket Pharmaceuticals | Reiterates: Buy | $48 | $3.33 | +1,341.44% | 4 | Sep 13, 2023 | |
| PRME Prime Medicine | Initiates: Buy | $18 | $3.48 | +417.99% | 1 | Apr 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $7 | $1.51 | +363.58% | 1 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $86 → $52 | $10.30 | +404.85% | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $23 → $25 | $107.97 | -76.85% | 4 | Jun 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $12 → $16 | $14.27 | +12.12% | 3 | Nov 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $285 | $23.65 | +1,105.07% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $1.55 | +1,190.32% | 1 | May 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $8.01 | - | 2 | Sep 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $23.15 | - | 1 | Jun 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $6.42 | - | 1 | Jun 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $0.84 | +1,328.57% | 1 | Jun 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $600 → $490 | $23.41 | +1,993.12% | 2 | Oct 23, 2017 |
Mirum Pharmaceuticals
Dec 16, 2025
Maintains: Buy
Price Target: $92 → $98
Current: $103.96
Upside: -5.73%
Abeona Therapeutics
May 16, 2025
Maintains: Buy
Price Target: $21 → $20
Current: $5.08
Upside: +293.70%
Editas Medicine
Dec 13, 2024
Downgrades: Hold
Price Target: $11 → $3
Current: $1.95
Upside: +53.85%
Soleno Therapeutics
Oct 1, 2024
Maintains: Buy
Price Target: $59 → $74
Current: $42.12
Upside: +75.69%
Fulcrum Therapeutics
Sep 12, 2024
Downgrades: Hold
Price Target: $22 → $3
Current: $9.90
Upside: -69.70%
Intellia Therapeutics
Sep 11, 2024
Maintains: Buy
Price Target: $80 → $64
Current: $12.36
Upside: +417.80%
Krystal Biotech
Sep 11, 2024
Maintains: Buy
Price Target: $204 → $220
Current: $269.13
Upside: -18.26%
Ultragenyx Pharmaceutical
May 31, 2024
Maintains: Buy
Price Target: $124 → $127
Current: $24.69
Upside: +414.38%
Rocket Pharmaceuticals
Sep 13, 2023
Reiterates: Buy
Price Target: $48
Current: $3.33
Upside: +1,341.44%
Prime Medicine
Apr 18, 2023
Initiates: Buy
Price Target: $18
Current: $3.48
Upside: +417.99%
Mar 24, 2023
Maintains: Buy
Price Target: $12 → $7
Current: $1.51
Upside: +363.58%
Aug 10, 2022
Downgrades: Hold
Price Target: $86 → $52
Current: $10.30
Upside: +404.85%
Jun 17, 2022
Maintains: Buy
Price Target: $23 → $25
Current: $107.97
Upside: -76.85%
Nov 15, 2021
Upgrades: Buy
Price Target: $12 → $16
Current: $14.27
Upside: +12.12%
Sep 7, 2021
Initiates: Buy
Price Target: $285
Current: $23.65
Upside: +1,105.07%
May 3, 2021
Initiates: Buy
Price Target: $20
Current: $1.55
Upside: +1,190.32%
Sep 8, 2020
Downgrades: Neutral
Price Target: n/a
Current: $8.01
Upside: -
Jun 17, 2020
Initiates: Neutral
Price Target: n/a
Current: $23.15
Upside: -
Jun 17, 2020
Initiates: Neutral
Price Target: n/a
Current: $6.42
Upside: -
Jun 17, 2020
Initiates: Buy
Price Target: $12
Current: $0.84
Upside: +1,328.57%
Oct 23, 2017
Maintains: Outperform
Price Target: $600 → $490
Current: $23.41
Upside: +1,993.12%